CG Oncology’s (CGON) Overweight Rating Reiterated at Cantor Fitzgerald

CG Oncology (NASDAQ:CGON)‘s stock had its “overweight” rating restated by investment analysts at Cantor Fitzgerald in a research report issued on Thursday, Benzinga reports. They currently have a $75.00 price objective on the stock. Cantor Fitzgerald’s target price would indicate a potential upside of 86.52% from the company’s current price.

Several other research firms have also weighed in on CGON. Morgan Stanley assumed coverage on shares of CG Oncology in a research note on Tuesday, February 20th. They set an “overweight” rating and a $55.00 price objective on the stock. The Goldman Sachs Group initiated coverage on shares of CG Oncology in a report on Tuesday, February 20th. They issued a “neutral” rating and a $42.00 price objective for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $75.00 price objective on shares of CG Oncology in a research note on Thursday, April 4th.

CG Oncology Trading Down 1.0 %

Shares of NASDAQ CGON traded down $0.41 during trading on Thursday, reaching $40.21. The company had a trading volume of 125,032 shares, compared to its average volume of 607,875. The business’s 50 day moving average is $39.91. CG Oncology has a 52 week low of $28.55 and a 52 week high of $50.23.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in CG Oncology stock. BNP Paribas Financial Markets acquired a new position in shares of CG Oncology, Inc. (NASDAQ:CGON) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 11,198 shares of the company’s stock, valued at approximately $492,000. 26.56% of the stock is owned by hedge funds and other institutional investors.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.